These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

470 related items for PubMed ID: 19743942

  • 1. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.
    Bessette L, Risebrough N, Mittmann N, Roussy JP, Ho J, Zlateva G.
    J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942
    [Abstract] [Full Text] [Related]

  • 2. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A, Krahn M, Naglie G.
    Arthritis Rheum; 2003 Jun 15; 49(3):283-92. PubMed ID: 12794781
    [Abstract] [Full Text] [Related]

  • 3. Minimizing complications from nonsteroidal antiinflammatory drugs: cost-effectiveness of competing strategies in varying risk groups.
    Spiegel BM, Chiou CF, Ofman JJ.
    Arthritis Rheum; 2005 Apr 15; 53(2):185-97. PubMed ID: 15818647
    [Abstract] [Full Text] [Related]

  • 4. A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model.
    Brereton N, Pennington B, Ekelund M, Akehurst R.
    J Med Econ; 2014 Sep 15; 17(9):677-84. PubMed ID: 24914585
    [Abstract] [Full Text] [Related]

  • 5. Economic evaluation of nonsteroidal anti-inflammatory drug strategies in rheumatoid arthritis.
    Inotai A, Mészáros A.
    Int J Technol Assess Health Care; 2009 Apr 15; 25(2):190-5. PubMed ID: 19366498
    [Abstract] [Full Text] [Related]

  • 6. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
    Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS.
    Health Technol Assess; 2008 Apr 15; 12(11):1-278, iii. PubMed ID: 18405470
    [Abstract] [Full Text] [Related]

  • 7. Costs and effects of various analgesic treatments for patients with rheumatoid arthritis and osteoarthritis in the Netherlands.
    Al MJ, Maniadakis N, Grijseels EW, Janssen M.
    Value Health; 2008 Apr 15; 11(4):589-99. PubMed ID: 18194404
    [Abstract] [Full Text] [Related]

  • 8. Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib?
    Rahme E, Hunsche E, Toubouti Y, Chabot I.
    Arthritis Rheum; 2006 Feb 15; 55(1):27-34. PubMed ID: 16463408
    [Abstract] [Full Text] [Related]

  • 9. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T, Wongbunnak R, Patcharatrakul T, Ratansumawong K, Poigampetch Y, Songpatanasilp T.
    J Med Assoc Thai; 2009 Dec 15; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective.
    Wielage R, Bansal M, Wilson K, Klein R, Happich M.
    Spine (Phila Pa 1976); 2013 May 15; 38(11):936-46. PubMed ID: 23250234
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Cost-effectiveness analysis of celecoxib versus non-selective non-steroidal anti-inflammatory drug therapy for the treatment of osteoarthritis in Spain: A current perspective].
    De Lossada A, Oteo-Álvaro Á, Giménez S, Oyagüez I, Rejas J.
    Semergen; 2016 May 15; 42(4):235-43. PubMed ID: 26006311
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Cost-utility analysis and economic burden of knee osteoarthritis treatment: the analysis from the real clinical practice.
    Turajane T, Chaweevanakorn U, Sungkhun P, Larbphiboonpong V, Wongbunnak R.
    J Med Assoc Thai; 2012 Oct 15; 95 Suppl 10():S98-104. PubMed ID: 23451446
    [Abstract] [Full Text] [Related]

  • 16. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC.
    Am J Manag Care; 2002 Oct 15; 8(15 Suppl):S401-13. PubMed ID: 12416790
    [Abstract] [Full Text] [Related]

  • 17. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
    Varas-Lorenzo C, Maguire A, Castellsague J, Perez-Gutthann S.
    Pharmacoepidemiol Drug Saf; 2007 Apr 15; 16(4):366-76. PubMed ID: 16897817
    [Abstract] [Full Text] [Related]

  • 18. Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents.
    You JH, Lee KK, Chan TY, Lau WH, Chan FK.
    Aliment Pharmacol Ther; 2002 Dec 15; 16(12):2089-96. PubMed ID: 12452942
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study.
    Rahme E, Bardou M, Dasgupta K, Toubouti Y, Ghosn J, Barkun AN.
    Rheumatology (Oxford); 2007 Feb 15; 46(2):265-72. PubMed ID: 16844699
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.